Mamotest has secured a $1.5 million investment from Philips Foundation to enhance its AI-driven breast cancer diagnostics, aiming to improve healthcare accessibility in underserved populations across Latin America and Europe.

Target Information

Mamotest, a healthcare startup based in Hub71 and part of Cohort 15 (2024), focuses on enhancing breast cancer diagnostics through innovative technologies. The company has successfully secured a total of $7 million in funding to date, including a recent $1.5 million investment from Philips Foundation Impact Investments, marking the foundation's inaugural support for a health tech firm from Latin America. Mamotest's mission is to democratize access to breast cancer care using artificial intelligence (AI) and real-world data, ensuring efficient and accurate diagnostic processes.

Industry Overview

The healthcare industry across Latin America is marked by significant disparities in access to essential services, particularly in underserved populations. In many regions, women face challenges in receiving timely breast cancer diagnostics and treatments, leading to preventable fatalities. The introduction of AI-driven solutions such as those offered by Mamotest represents a critical step toward addressing these disparities, providing enhanced diagnostic capabilities and streamlined patient journeys.

In countries like Argentina, Mexico, Brazil, and Spain, where Mamotest operates, advancements in digital health and innovation are being embraced. The COVID-19 pandemic has further accelerated the adoption of telemedicine and remo